Literature DB >> 2232063

The HIV-testing policies of US hospitals.

C E Lewis1, K Montgomery.   

Abstract

To determine the human immunodeficiency virus-testing policies adopted by US hospitals, we surveyed a stratified random sample of all nonfederal general acute care hospitals, drawn from the American Hospital Association's 1987 database. Interviews were completed with the chief administrator in 561 hospitals (response rate, 78.4%). Two thirds of hospitals have admitted at least one patient with the acquired immunodeficiency syndrome, and over 83% have formal written policies about human immunodeficiency virus testing. Most contain provisions protecting patients' rights; eg, 78% require pretest informed consent, 66% require a special human immunodeficiency virus-testing consent form, and 75% require that patients who test seropositive be so informed. Many policies also contain provisions that protect providers; eg, 56% require that test results appear in patients' records, 38% require review of treatment plans when a patient tests seropositive, and 3% require transferring such patients. Hospital characteristics are not strongly associated with the adoption of testing policies.

Entities:  

Keywords:  Empirical Approach; Health Care and Public Health

Mesh:

Year:  1990        PMID: 2232063

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  3 in total

1.  Mode of Detection of HIV Infection - A Retrospective Study of 612 Cases.

Authors:  Y K Sharma; S K Sayal
Journal:  Med J Armed Forces India       Date:  2011-05-30

2.  Guidelines for designing rapid assessment surveys of HIV seroprevalence among hospitalized patients. Centers for Disease Control and Prevention.

Authors:  B Schwartländer; R S Janssen; G A Satten; S E Critchley; L R Petersen; T J Dondero
Journal:  Public Health Rep       Date:  1994 Jan-Feb       Impact factor: 2.792

3.  Knowledge, attitudes and practices of Greek health professionals, in relation to AIDS.

Authors:  A Roumeliotou; E Kornarou; V Papaevangelou; P Spiropoulou; E Ktenas; G Stergiou; G Papaevangelou
Journal:  Eur J Epidemiol       Date:  1992-11       Impact factor: 8.082

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.